Cellectis SA reported a consolidated net loss attributable to shareholders of $41.3 million, or $0.41 per share, for the nine-month period ended September 30, 2025, compared to a net loss of $42.7 million, or $0.49 per share, for the same period in 2024. The period included a $5.8 million loss from fair value remeasurement of warrants issued to the European Investment Bank, a $16.7 million increase in foreign exchange loss, and a $7.5 million decrease in loss on fair value of investment in shares of Cibus, Inc. Cash inflows included $30.5 million from revenue, $7.1 million in interest from financial and cash-equivalent investments, and $2.9 million from credit VAT. Cash outflows included $35.5 million to suppliers, $32.4 million for wages, bonuses, and social expenses, $8.1 million for lease debt payments, $4.0 million repayment of the "PGE" loan, and $3.0 million for capital expenditures. Cellectis plans to focus its cash spending on developing its pipeline, including manufacturing and clinical development of lasme-cel, eti-cel, and other potential product candidates.